Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting
Acquisition of Zephyr(R) EBV Technology Enables Pulmonx to Develop Both Assessment Tools and Therapeutic Solutions for Emphysema
“This acquisition provides Pulmonx with a strengthened ability to deliver innovative therapeutic solutions to emphysema patients and their physicians,” said
Treatment of emphysema by ELVR using the Emphasys EBV has been shown in the Endobronchial Valve for Emphysema PalliatioN Trial, known as VENT, to improve lung function, exercise tolerance and quality of life for some patients.(1) More recent research suggests that inter-lobar collateral flow in the lungs, known as collateral ventilation, can limit the effectiveness of ELVR.(2),(3) Pulmonx has developed its Chartis System to identify the presence of collateral ventilation in the lungs. This may enable physicians to better identify patients who could benefit from ELVR and also confirm the effectiveness of valve placement by measuring air flow following EBV deployment.
Earlier this year, Pulmonx submitted an application to the U.S. Food and Drug Administration (FDA) to market the Chartis System in
“There is significant data and broad physician support that suggests ELVR using the Emphasys EBV can be effective but that patient selection and valve placement are the critical factors in improving the probability of success of the therapy,” added Dr.
Pulmonx’s newly expanded product portfolio will be unveiled at the Pulmonx booth (1205) at
“Emphasys was a true pioneer in EBV therapy, and we have gained tremendous institutional knowledge through the acquisition,” said
Pulmonx Corporation, based in
(1) Emphasys Medical PMA P070025 Panel Presentation,
(2) Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.
(3) Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.
SOURCE Pulmonx Corporation